… misplaced as the deflationary effects of the credit crunch were to slow the global economy. Western … problems were easing. The spreads between corporate bonds and government stock were narrowing, which he … borrowers were still able to access the bond market. We were appointed by Anglo American, … ...

… ago. Between the economic downturn and the credit crunch, the company has been scrounging for cash … deal, borrowing more money, or issuing more bonds. “Compared to a wide range of alternatives … ...

… a wages breakout. Instead, Pacific Brands’ Chesty Bond, Berlei and Holeproof workers are the victims … The line would be that the global credit crunch overwhelmed the local demand stimulus from the … ...

… as a sub-prime surprise, then became a credit crunch and is now a global financial crisis. … is about to hit national and international bond markets. The born-again Keynesians seem to have … 19th century, governments changed the terms of bonds that they issued through a process known … ...

Read full story for latest details. ...

Here is a recap of the top news items of the week on Wall Street: 1. Confirming what many had already expected, Citi (NYSE: C) announced Friday that the U.S. government will take a 36% stake in it, issuing common stock in exchange for preferred securities, increasing its tangible common equity without any further investment. Specifically, Citi will...

The Trading Radar highlights key earnings and economic announcements for tomorrow’s trading session: Before Market Opens: Economics: 8:30am ET Personal Income/Spending for Jan. Core PCE for Jan. - Street expects 0.1% Earnings: Allied Capital (NYSE: ALD) - consensus EPS $0.22 American Capital (Nasdaq: ACAS) - consensus EPS $0.64 ATP Oil &am...

Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) 81.8% LOWER; received a Complete Response Letter from the FDA for its New Drug Application (NDA) for Silenor for the treatment of insomnia. Based on its review, the FDA has determined that the NDA cannot be approved in its present form. Synta Pharmaceuticals Corp. (NASDAQ: SNTA) 78.6% LOWER; said based o...

StreetInsider.com Morning Movers: Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) 83% LOWER; received a Complete Response Letter from the FDA for its New Drug Application (NDA) for Silenor for the treatment of insomnia. Based on its review, the FDA has determined that the NDA cannot be approved in its present form. Synta Pharmaceuticals Corp. (NASDAQ:...

UPGRADES: RBC Capital upgrades Verizon (NYSE: VZ) from Sector Perform to Outperform. Goldman Sachs upgrades Anglo American (Nasdaq: AAUK) from Neutral to Buy. Piper Jaffray & Co. upgrades Gibraltar Industries (Nasdaq: ROCK) from Sell to Neutral. Price target lowered from $11 to $6. Here is StreetInsider.com’s summary of the upgrade. For d...